Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20859581 | 1.00 | KDM4E (0.67) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL9312119 | 0.98 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL9314179 | 0.91 | — | — | |
| SCHEMBL11326199 | 0.83 | EPHX1 (0.52) | ALDH1A1LMNAMAPTABCC4ZDHHC20 | |
| SCHEMBL31208245 | 0.82 | ALDH1A1 (0.46) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL273387 | 0.82 | — | — | |
| SCHEMBL1900654 | 0.82 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL6516953 | 0.82 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14740196 | 0.82 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1847535 | 0.82 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022115651-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | HEPION PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220168385-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | ACHILLE LIFE SCIENCES LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-2914256-B1 | DISUBSTITUTED AMINO ACIDS AND METHODS OF PREPARATION AND USE THEREOF | AILERON THERAPEUTICS INC (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3461835-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ContraVir Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2018106928-A1 | TREATMENT AND PREVENTION OF HBV DISEASES BY CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACIDES 1 AND 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9714271-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714271-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160207961-A1 | Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3 | ACHILLE LIFE SCIENCES LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160207961-A1 | Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3 | ACHILLE LIFE SCIENCES LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9200038-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CICLOFILIN PHARMACEUTICALS CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| US-9200038-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CICLOFILIN PHARMACEUTICALS CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| US-20140142033-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ISOTECHNIKA PHARMA INC. (CA) | 2014-05-22 | — | — | US | disclosed |
| US-20140142033-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ISOTECHNIKA PHARMA INC. (CA) | 2014-05-22 | — | — | US | disclosed |
| US-20130190223-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | ISOTECHNIKA PHARMA INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| US-20130190223-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | ISOTECHNIKA PHARMA INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| WO-2012079172-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ISOTECHNIKA PHARMA INC. (CA) | 2012-06-21 | — | — | WO | disclosed |
| WO-2010012073-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | ISOTECHNIKA LABS INC. (CA) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190223-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | CD40, FKBP1A, FKBP4 | KDM4E 3106/4885MAPK1 3138/4885HIF1A 1044/4885 |
| US-20160207961-A1 | Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3 | FKBP1A, CHP1, FKBP3 | KDM4E 3615/4885MAPK1 2179/4885HIF1A 2427/4885 |
| US-20220168385-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | SERPINC1, CHP1, FGB | KDM4E 4443/4885MAPK1 2846/4885HIF1A 2142/4885 |
| US-20140142033-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | FKBP1A, CHP1, FKBP3 | KDM4E 3615/4885MAPK1 2179/4885HIF1A 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.